Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Analyst Group: Equity Research Report on SoftOx Solutions - Addressing the Infection That Antibiotics Cannot Eradicate

SOFTXPress release2026-10-28 09:08

SoftOx Solutions AS (“SoftOx” or “the Company”) addresses a limitation that antibiotics have not overcome: bacteria embedded in biofilm within the airways of patients with cystic fibrosis (“CF”) and non-CF bronchiectasis (“NCFB”), where treatment suppresses the infection without eradicating it. SoftOx Inhalation Solution (“SIS”) stabilizes hypochlorous acid, an endogenous antimicrobial produced by the body’s neutrophils, and delivers it by nebulization into the airway together with an organic acid. With a pan-antimicrobial mechanism, safety established in two clinical studies and proof of concept expected during H1-27, Analyst Group considers SoftOx well positioned ahead of its key value inflection. Based on an rNPV model, we derive a present value of NOK 0.20 per share in a Base scenario, rising to approx. NOK 0.30 following a positive readout, with or without a subsequent licensing agreement.


Read the equity research report here


About Analyst Group: One of the Nordics’ leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on SoftOx Solutions. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.